Shots:
- Sensei Biotherapeutics has dosed the first patient in P-Ib/II (FTH-PIK-101) trial assessing PIKTOR (serabelisib & sapanisertib) + fulvestrant &/or other anticancer therapies in pts with HR+/HER2- advanced or metastatic breast cancer
- PIKTOR was evaluated in the P-Ib study in heavily pretreated advanced breast, endometrial, & ovarian cancers, where PIKTOR + paclitaxel achieved a 47% ORR (n=15), rising to 71% in tumors with PI3K pathway mutations, incl. 3CRs in endometrial cancer
- Additionally, Sensei is conducting an ongoing open-label P-II (FTH-PIK-201) study of PIKTOR in ~40 pts with advanced endometrial cancer
Ref: Businesswire | Image: Sensei Biotherapeutics | Press Release
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
